drug_type
RELEVANT_DRUG
intervention_type
Oncolytic virotherapy
drug_description
An intratumoral, engineered oncolytic adenovirus (also known as suratadenoturev/Telomelysin) that uses the hTERT promoter for selective replication in telomerase-positive cancer cells, inducing oncolysis and immunogenic tumor antigen release.
nci_thesaurus_concept_id
C119617
nci_thesaurus_preferred_term
Suratadenoturev
nci_thesaurus_definition
A replication-competent oncolytic, telomerase-specific adenovirus serotype 5 (Ad5), with potential antineoplastic activity. Suratadenoturev contains the human telomerase reverse transcriptase (hTERT) gene promoter sequence that drives the expression of the E1A and E1B genes, and is linked to an internal ribosomal entry site (IRES). Upon administration, OBP-301 selectively infects and replicates in cancer cells that are expressing telomerase, which causes cell lysis. This adenovirus does not infect or replicate in normal, healthy cells. OBP-301 may also potentially be used as a chemosensitizer. hTERT, which encodes for the catalytic protein subunit of telomerase, is overexpressed in a variety of cancer cell types but not in normal, healthy cells. The insertion of an IRES further improves selectivity towards telomerase-expressing cancer cells.
drug_category
ONCOLYTIC VIRUS
drug_class
Gene therapy
drug_delivery_route
Intratumoral
drug_mechanism_of_action
Replication-competent adenovirus (Ad5) engineered with the hTERT promoter driving E1A/E1B expression (via IRES) to enable selective replication in telomerase-positive tumor cells. Intratumoral infection leads to tumor-selective oncolysis, releasing tumor antigens and danger signals that can prime antitumor immunity, with minimal replication in normal cells.
drug_name
OBP-301
nct_id_drug_ref
NCT06340711